Bicara Therapeutics to report Q1 2026 financial results and updates on May 11

Bicara Therapeutics, a clinical-stage biopharmaceutical company focused on bifunctional therapies for solid tumors, will announce its Q1 2026 financial results and business updates on May 11, 2026, before market open. The company will hold a conference call at 8:30 a.m. ET the same day to discuss these results. Bicara is developing ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β, aimed at treating head and neck squamous cell carcinoma and other solid tumors. This update is important as it may provide insights into the progress of their lead drug candidate and ongoing clinical trials.